Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.68 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.68 |
| ▸ | ITGA2B | P08514 | 18/20 | 0.68 |
| ▸ | ITGB6 | P18564 | 10/20 | 0.68 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.68 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.60 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857772 | 0.93 | ITGB3 (0.79) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL2837768 | 0.93 | ITGAV (0.68) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL5856660 | 0.93 | ITGAV (0.68) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL5859346 | 0.92 | ITGB3 (0.78) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL5857007 | 0.91 | ITGB3 (0.66) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL2836463 | 0.91 | ITGAV (0.67) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL2834559 | 0.90 | ITGB3 (0.69) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL5858080 | 0.90 | ITGAV (0.80) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL2871983 | 0.89 | ITGAV (0.62) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL2836417 | 0.89 | ITGAV (0.63) | ITGAVITGB3ITGA2BITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119098-B2 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-6933304-B2 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| EP-1289983-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-09-19 | — | — | US | disclosed |
| WO-2001096334-A2 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133023-A1 | Heteroarylalkanoic acids as integrin receptor antagonists | ITGA5, ITGA2B, ITGAV | ITGAV 3/4885ITGB3 5/4885ITGA2B 2/4885 |
| US-20040092497-A1 | Heteroarylakanoic acids as intergrin receptor antagonists | ITGA5, ITGB7, ITGA2B | ITGAV 13/4885ITGB3 5/4885ITGA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.